The Life Sciences Law Review – Edition 7: Argentina
THE LAW REVIEWS
The pharmaceutical industry continues to be a highly regulated sector that has a very important presence in Argentina. Its financial results are highly affected by the influence of agreements entered into with social security organisations – mainly the social security organisation that covers retired people – and private health insurance companies. These organisations agree on coverage that favours its affiliates with regard to prices from laboratories, wholesalers and pharmacies. Despite the fact that these kinds of agreements continue to be in place, at least until March 2019, there has been a change in the financial politics these organisations have, owing to the fact that they are now calling for bids and joint purchases of certain products – mainly those related to oncologic and special treatment prognosis, which are usually the most expensive products. With the exception of the registration of biological products, not many changes have occurred during 2018 regarding the issuance of regulations. Carlos A Chiale continues as head of the National Administration of Drugs, Food and Medical Devices (ANMAT).
Palabras clave: Derecho de la Salud · Life Sciences
Reproducido con el permiso de Law Business Research Ltd. Este artículo se publicó primero en abril 2019. Para más información, por favor contactar a Nick.Barette@thelawreviews.co.uk
